BridgeBio Pharma, Inc. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
BridgeBio Pharma, Inc. (BBIO) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $1.40 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2026-08-10
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $1.40M.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $2.20M.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $700.00K.
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $1.40M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $1.40M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $2.20M 10-Q · filed 2026-05-07 |
| 2025-09-30 | $700.00K 10-Q · filed 2025-10-29 |
| 2025-06-30 | $1.40M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $2.00M 10-Q · filed 2025-04-29 |
| 2024-09-30 | $600.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $1.20M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $1.80M 10-Q · filed 2024-05-02 |
| 2023-09-30 | $600.00K 10-Q · filed 2023-11-02 |
| 2023-06-30 | $1.20M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $1.80M 10-Q · filed 2023-05-04 |
| 2022-09-30 | $600.00K 10-Q · filed 2022-11-03 |
| 2022-06-30 | $1.20M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $1.80M 10-Q · filed 2022-05-05 |
| 2021-09-30 | $1.20M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $900.00K 10-Q · filed 2021-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |